Spinal Anesthesia of a Patient with Central Core Disease for Caesarean Section: A Case Report
Keywords:Central core disease, Congenital myopathy, General anesthesia, Malignant hyperthermia, Spinal anesthesia
Central core disease is an autosomal dominant congenital myopathy. It typically manifests as muscle weakness and developmental delay. Central core disease is also associated with malignant hyperthermia which can be developed by volatile agent or succinylcholine. Here, we are reporting a case of a 34-year-old primigravida with central core disease who underwent an emergency cesarean section under spinal anesthesia without complications.
Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956; 79: 610–2.
Ronald D. Miller. Miller`s anesthesia 8th edition Volume 1 1130
Denborough MA, Dennet X, Anderson RM. Central-core disease and malignant hyperpyrexia. British Medical Journal 1973; 1: 272–3.
Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008; 8: 319–26
A K Brownell, R T Paasuke. Use of local anesthetics in malignant hyperthermia. CMAJ. 1986 May 1; 134(9): 993–994.
A J McKenzie, K G Couchman, N Pollock. Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intensive Care. 1992 May;20(2):165-8. doi: 10.1177/0310057X9202000208
Liguo HuJianhui, PanShantang, ZhangJinjing, YuKeqiang, HeShuhua, ShuRuiting Wang. Propofol in combination with remifentanil for cesarean section:Placental transfer and effect on mothers and newborns at differentinduction to delivery intervals. Taiwanese Journal of Obstetrics and Gynecology Volume 56, Issue 4, August 2017, Pages 521-526
A.P. Georgiou, J. Gatward. Emergency anaesthesia in central core disease. BJA CORRESPONDENCE VOLUME 100, ISSUE 4, P567, APRIL 01, 2008
How to Cite
Copyright (c) 2021 Se Jin Kim , Yeon Ji Roh, So Yeon Cho , Jangho Bae, Seongsik Kang
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.